References
- Arcamone F., Bernardi L., Giardion P. Synthesis and antitumour activity of 4–demethoxydaunorubicin, 4-de-methoxy-7, 9-diepidaunorubicin and their anomers. Cancer Treat. Rep. 1976; 60: 829–34
- Di Marco A., Casazza A. M., Pratesi G. Antitumour activity of 4-demethoxydaunorubicin administered orally. Cancer Treat. Rep. 1977; 61: 893–4
- Casazza A. M. Experimental evaluation of anthracycline analogues. Cancer Treat. Rep. 1979; 63: 835–44
- Casazza A. M., Pratesi G., Giuliani F., Di Marco A. Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori 1980; 64: 549–64
- Di Marco A., Zunio F., Casazza A. M. Comparison of biochemical and biological methods in the evaluation of new anthracycline drugs. Antibiot Chemother 1978; 23: 12–20
- Casazza A. M., Di Marco A., Bonadonna G. Effects of modifications in position 4 of the chromophore or in position 4′ of the amino sugar on the antitumour activity and toxicity of daunorubicin and doxorubicin. Anthracyclines: current status and new developments, S. T. Crooke, S. D. Reich. Academic Press, New York 1980; 403–30
- Casazza A. M., Bertazolli C., Pratesi G. Antileukemic activity and cardiac toxicity of 4-demethoxydaunorubicin. Proc. Am. Assoc. Canc. Res. 1979; 29: 16
- Bennt J. IM., Catovsky D., Daniel M. T. Proposed revised criterial for the classification of acute myeloid leukaemia. Ann. In. Med. 1985; 103: 626–9